NUK - logo
E-resources
Peer reviewed
  • Proteome-wide Anti-HCV and ...
    Burbelo, Peter D.; Kovacs, Joseph A.; Ching, Kathryn H.; Issa, Alexandra T.; Iadarola, Michael J.; Murphy, Alison A; Schlaak, Joerg F.; Masur, Henry; Polis, Michael A.; Kottilil, Shyam

    The Journal of infectious diseases, 09/2010, Volume: 202, Issue: 6
    Journal Article

    We quantified antibody responses to the HCV proteome that are associated with sustained virologic response (SVR) in HIV/HCV co-infected patients treated with pegylated interferon and ribavirin. Analysis of pre- and post-treatment samples revealed significant decreases in the combined anti-core, anti-E1 and anti-NS4 HCV antibody titers in those with SVR, but not in the relapsers or non-responders. Furthermore, anti-p24 HIV antibody titers inversely correlated with treatment response. These results suggest that profiling anti-HCV antibody is useful for monitoring HCV therapy especially in discriminating between relapsers and SVRs at 48 weeks.